相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea
Srdan Verstovsek et al.
CANCER (2014)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Emil T. Kuriakose et al.
HAEMATOLOGICA (2013)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia
Juan-Carlos Hernandez-Boluda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Jean-Jacques Kiladjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
Giovanni Barosi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy
Francesca Palandri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi et al.
BLOOD (2007)
The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders
Thomas Stauffer Larsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group
G. Barosi et al.
LEUKEMIA (2007)
Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia
L. Shvidel et al.
LEUKEMIA (2007)
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and NIMM patients with clonal hematopoiesis
Ross L. Levine et al.
BLOOD (2006)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial
G Finazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
